Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Genentech Gets Non-Hodgkin’s Lymphoma Candidate With Seattle Genetics Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

SGN-40 will be examined for potential use with and without Rituxan.
Advertisement

Related Content

Seattle Genetics CEO Clay Siegall: An Interview With “The Pink Sheet” DAILY (Part 1 Of 2)
Seattle Genetics CEO Clay Siegall: An Interview With “The Pink Sheet” DAILY (Part 1 Of 2)
Seattle Genetics Seeks To “Change The Treatment Paradigm” For Non-Hodgkin’s Lymphoma
Seattle Genetics Seeks To “Change The Treatment Paradigm” For Non-Hodgkin’s Lymphoma
Astellas' Once-Daily Prograf Receives Mixed Decisions For Three Prophylaxis Claims
Astellas’ Once-Daily Prograf Receives Mixed Decisions For Three Prophylaxis Claims
Astellas’ Once-Daily Prograf Receives Mixed Decisions For Three Prophylaxis Claims

Topics

Advertisement
UsernamePublicRestriction

Register